EN DE
Watch Yungjin Pharm Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Yungjin Pharm Co Ltd (003520) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Yungjin Pharm Co Ltd stock KRW 329, price KRW 826, that is 60.2% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7003520004

YP Yungjin Pharm Co Ltd logo Thin data Nov 7, 2026

Yungjin Pharm Co Ltd

003520 · KO
Very expensive, weak quality

Our calculation puts a fair price 60% below what the stock costs today.

Quality 41/100
Expensive Growth (revenue 5y +4.1 %/yr in KRW)
Moderate debt
Revenue last quarter 16% below a year ago.
Fair value 328.52 KRW · Strongly overvalued
Loss-making · -3.3% net margin (TTM)
Negative free cash flow
Trails peers (2/10)
Narrow moat 11/100
Thin data
Watch Yungjin Pharm Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

6,090 KRW 826.00 KRW Fair Value 328.52 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range 826.00 KRW – 6,090 KRW · fair‑value band 245.16 KRW – 490.33 KRW · the 826.00 KRW price screens above the 328.52 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Yungjin Pharm Co in your weekly email

Every Wednesday you see whether Yungjin Pharm Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally.

Show moreShow less

The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products.

It also provides vitamins, minerals, and other products; and APIs. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as a subsidiary of KT&G Corporation.

Stock analysis

Yungjin Pharm Co Ltd (003520) currently trades at 826.00 KRW, while our model-based Fair Value estimate is 328.52 KRW, 60% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 394.72 KRW per share, and 0 of the 5 models we run sit above the 826.00 KRW price.

Bear case: the Earnings-Based group reads lowest at 63.76 KRW, and 5 of the 5 models stay below the price. Data coverage for this calculation is low.

Scenario range: 245.16 KRW (bear) to 490.33 KRW (bull), the price of 826.00 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Yungjin Pharm Co Ltd reported revenue of 254B KRW in FY2025 versus 196B KRW in FY2021, a compound +6.7%/yr. Reported net income was −228M KRW in FY2025.

Key figures

Market cap 152B KRW (≈ $112M) Micro · P/S ratio 0.97 · EPS (TTM) −31.95 KRW · Net margin −3.3% · Return on equity −5.0% · Return on assets (EBIT) −0.8% (5-year average) · Operating margin −6.7% · Revenue (TTM) 179B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 11 out of 100 (medium confidence).

What moves the price

The share trades about 62% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −60%, 003520 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (63.76 KRW to 691.42 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 245.16 KRW Fair Value 328.52 KRW Bull 490.33 KRW
Price 826.00 KRW · Downside -60.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 44.63 KRW 63.76 KRW 79.35 KRW 73
ROIC Compounder 44.63 KRW 63.76 KRW 79.35 KRW 72
EV/EBITDA 431.05 KRW 691.42 KRW 951.79 KRW 66
All 6 models by family
Earnings-Based
EPV 44.63 KRW 63.76 KRW 79.35 KRW 73
Multiples
EV/EBIT n/a 98.02 KRW 210.04 KRW 61
EV/EBITDA 431.05 KRW 691.42 KRW 951.79 KRW 66
EV/Revenue n/a n/a 95.38 KRW 50
Asset-Based
NCAV (Graham) 245.16 KRW 328.52 KRW 490.33 KRW 54
Economic Profit
ROIC Compounder 44.63 KRW 63.76 KRW 79.35 KRW 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 34
How much profit the company makes from its sales and capital
Quality Growth 26
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 35
Debt, balance sheet and risk of trouble
Investment 79
Does it invest with discipline instead of growing at any price?
Low Volatility 69
How calm the share price moves, does not count
Price momentum 4
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 21/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Start year 2020 (pandemic). Over 10 years: +4.1% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.2% (2020) → 1.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

003520 screens overvalued: fair value 60% below the price. Compare with Merck KGaA →

Compare Yungjin Pharm Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −60.2% · Bottom 25%
Profitability
Return on assets −0.1% · Below median
Net margin (12 months) −3.3% · Bottom 25%
Operating margin (12 months) −6.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −16.0% · Bottom 25%
Balance sheet
Debt / equity 0.53× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.66× · Cheaper than median
P/S (12 months) 0.85× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)73 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs 003520
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs 003520
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs 003520
Haleon plc HLN $9.14 $8.61 −6% vs 003520
Merck KGaA MRK €148.75 €109.18 −27% vs 003520
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs 003520
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 003520
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 003520
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs 003520
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs 003520

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Yungjin Pharm Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Yungjin Pharm Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/003520

Frequently asked questions

Is Yungjin Pharm Co Ltd (003520) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 328.52 KRW versus a price of 826.00 KRW, about 60% lower (overvalued).
What is the fair value of 003520?
Our model-based fair value for Yungjin Pharm Co Ltd is 328.52 KRW (as of Nov 7, 2026), built from audited fundamentals. The current price: 826.00 KRW.
What is the quality score of 003520?
Yungjin Pharm Co Ltd has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Yungjin Pharm Co Ltd (003520)?
Our model-based price target is the fair value of 328.52 KRW (as of Nov 7, 2026) from 6 valuation models. Cautious scenario 245.16 KRW, optimistic scenario 490.33 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Yungjin Pharm Co Ltd stock forecast for 2026?
Our models put fair value at 328.52 KRW, about 60% lower versus a price of 826.00 KRW (overvalued). Cautious scenario 245.16 KRW, optimistic scenario 490.33 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Yungjin Pharm Co Ltd (003520)?
Yungjin Pharm Co Ltd reported trailing-twelve-month revenue of about 179B KRW (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Yungjin Pharm Co Ltd (003520)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Yungjin Pharm Co Ltd it is 328.52 KRW per share (as of Nov 7, 2026), against a price of 826.00 KRW. It is the blended result of 6 valuation models in 4 families (Earnings-Based, Multiples, Asset-Based, Economic Profit).
Is Yungjin Pharm Co Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 003520 trades above its calculated fair value: price 826.00 KRW, fair value 328.52 KRW, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 003520?
No. The price is what the market pays today (826.00 KRW); the fair value is what the company's own numbers justify (328.52 KRW). For Yungjin Pharm Co Ltd the two are 497.48 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Yungjin Pharm Co Ltd worth?
The market values Yungjin Pharm Co Ltd at about 152B KRW (market capitalisation, as of Nov 7, 2026). Per share that is 826.00 KRW; our models calculate a fair value of 328.52 KRW per share.
What do the bullish and bearish scenarios say about 003520?
Our models span a range for Yungjin Pharm Co Ltd: cautious scenario 245.16 KRW, base 328.52 KRW, optimistic 490.33 KRW per share (as of Nov 7, 2026, price 826.00 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Yungjin Pharm Co Ltd (003520)?
Balance-sheet figures for Yungjin Pharm Co Ltd (as of Nov 7, 2026): return on equity −5.0%, debt of 0.53 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 003520 from its 52-week high?
Yungjin Pharm Co Ltd trades at 826.00 KRW, about 62% below its 52-week high of 2,170 KRW and at the low of 826.00 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 328.52 KRW is for.
Which stocks are comparable to Yungjin Pharm Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Yungjin Pharm Co Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price 826.00 KRW, calculated fair value 328.52 KRW (−60%), Quality Score 41/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 003520 calculated?
We run Yungjin Pharm Co Ltd through 6 models from 4 families: Earnings-Based, Multiples, Asset-Based, Economic Profit. Every model gets the same audited fundamentals; the fair value of 328.52 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Yungjin Pharm Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Yungjin Pharm Co Ltd (003520)?
The closing price on Nov 6, 2026 was 826.00 KRW. Our model-based fair value is 328.52 KRW, about 60% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Yungjin Pharm Co Ltd right now?
The price sits above even our optimistic bull case (490.33 KRW). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (245.16 KRW to 490.33 KRW) leaves room in how you read the outcome.

Key figures of Yungjin Pharm Co Ltd

How large is the market capitalisation of Yungjin Pharm Co Ltd (003520)?
The market capitalisation of Yungjin Pharm Co Ltd is 152B KRW (≈ $112M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Yungjin Pharm Co Ltd (003520)?
The price-to-sales ratio of Yungjin Pharm Co Ltd is 0.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Yungjin Pharm Co Ltd (003520)?
Earnings per share at Yungjin Pharm Co Ltd are −31.95 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Yungjin Pharm Co Ltd (003520)?
The net margin of Yungjin Pharm Co Ltd is −3.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Yungjin Pharm Co Ltd (003520)?
The return on equity (ROE) of Yungjin Pharm Co Ltd is −5.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Yungjin Pharm Co Ltd (003520)?
On an EBIT basis the return on assets of Yungjin Pharm Co Ltd is −0.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Yungjin Pharm Co Ltd (003520)?
The operating margin of Yungjin Pharm Co Ltd is −6.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Yungjin Pharm Co Ltd (003520)?
Revenue at Yungjin Pharm Co Ltd is growing −16.0% versus a year earlier (3y avg +5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Yungjin Pharm Co Ltd (003520)?
Earnings per share at Yungjin Pharm Co Ltd are growing −35.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Yungjin Pharm Co Ltd (003520) generate?
The free cash flow of Yungjin Pharm Co Ltd is −234M KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Yungjin Pharm Co Ltd (003520) carry?
The net debt of Yungjin Pharm Co Ltd is 64.0B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Yungjin Pharm Co Ltd in the live analysis

One click puts Yungjin Pharm Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.